Why 80% of Autoimmune Patients Are Women: The Estrogen Connection

Approximately 80% of people with autoimmune diseases are women. This is not coincidence; it is biology. A comprehensive review published in Frontiers in Immunology examined how sex hormones, particularly estrogen, drive this disparity through complex immune-modulating effects that change across the lifespan.

The relationship between estrogen and immune function is not simple. Nearly all immune cells possess estrogen receptors, and estrogen can be both pro-inflammatory and anti-inflammatory depending on circulating levels and which cell-specific receptors are activated. Higher estrogen levels generally strengthen immune surveillance, which protects against infection but increases the risk that the immune system will target the body's own tissues. This explains the paradox: women's stronger immune response is both a survival advantage and an autoimmune vulnerability.

Life-stage hormonal transitions are particularly risky. The fluctuating estrogen levels during menstruation, pregnancy, and perimenopause can trigger or exacerbate autoimmune conditions including lupus, rheumatoid arthritis, multiple sclerosis, and Hashimoto's thyroiditis. During pregnancy, when estrogen and progesterone are elevated and stable, symptoms of RA and MS often improve, only to flare postpartum when hormone levels crash. Women with lupus show the opposite pattern: symptoms worsen during pregnancy.

Androgens, by contrast, are primarily protective against autoimmunity, which partially explains the lower rates in men. But men are not immune. Male autoimmune disease, though less prevalent, tends to present later in life when testosterone levels have declined, reinforcing the hormonal protection hypothesis.

The Tracking Connection

Kairos™ tracks hormonal changes alongside immune markers, symptom flares, and inflammatory indicators over time. For users managing or at risk for autoimmune conditions, this longitudinal view can reveal whether symptom patterns correlate with hormonal transitions, providing clinicians with the temporal data they need to adjust treatment during high-risk windows rather than reacting after flares occur.